Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Sodium chloride
Drug ID BADD_D02473
Description Sodium chloride, also known as salt, common salt, table salt or halite, is an ionic compound with the chemical formula NaCl, representing a 1:1 ratio of sodium and chloride ions. Sodium chloride is the primary salt in seawater and in the extracellular fluid of many multicellular organisms. It is listed on the World Health Organization Model List of Essential Medicines.
Indications and Usage This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives.
Marketing Status approved; vet_approved
ATC Code A12CA01; B05CB01; B05XA03
DrugBank ID DB09153
KEGG ID D02056
MeSH ID D012965
PubChem ID 5234
TTD Drug ID D04YZL
NDC Product Code 76420-083; 80327-011; 82529-000; 10106-3301; 81861-0026; 82056-0001; 24208-277; 42829-001; 46163-300; 51662-1258; 51879-122; 52584-888; 52584-966; 57826-441; 0338-0160; 63323-093; 63323-187; 63323-632; 63323-924; 65219-222; 0409-1141; 69842-284; 0536-1254; 70529-022; 70529-049; 71872-7084; 79672-613; 80762-0010; 81826-001; 24600-1386; 17271-700; 24208-385; 52584-186; 0264-1800; 0264-2201; 0264-5804; 0264-7805; 0338-9151; 65219-472; 65282-1505; 65282-1510; 0404-9953; 69842-285; 70529-136; 70795-1120; 71872-7248; 76297-001; 80762-0012; 24600-1138; 0990-7730; 11822-0470; 49230-300; 0220-3593; 0220-3597; 0220-3599; 54973-4080; 59390-183; 0338-0047; 63323-623; 65219-226; 65219-468; 65219-474; 0404-9955; 68428-885; 70369-007; 70369-010; 54973-6433; 0338-0054; 62106-5206; 63323-090; 63323-186; 0363-5558; 0363-7500; 65219-470; 0409-1966; 0536-1253; 0641-6144; 73666-0580; 77267-007; 80771-000; 0990-7138; 55579-937; 17478-622; 50090-2488; 0220-3598; 51662-1577; 0264-7802; 58264-0135; 0338-0050; 0338-0051; 0338-0182; 0338-0553; 0338-9543; 0363-1505; 63323-088; 64117-867; 65219-220; 65219-230; 65219-232; 0404-9978; 80327-009; 11014-0075; 24874-0001; 49452-6690; 49452-6700; 0990-7983; 11822-0469; 17271-701; 42829-505; 51662-1318; 0264-7800; 0264-9375; 54973-4095; 55681-305; 0338-0186; 0338-0192; 63323-095; 63323-626; 0363-9050; 0409-4888; 0409-7101; 71872-7083; 73666-0550; 73666-0560; 73666-0570; 14639-6444; 70343-210; 70387-109; 11822-5458; 42829-003; 51662-1464; 0264-7806; 55154-4358; 0338-0162; 0338-0166; 63323-530; 65219-466; 0487-4301; 69626-0064; 69842-533; 70529-021; 76328-100; 10695-153; 24208-276; 0220-3586; 0220-3590; 51662-1342; 51879-191; 0264-5802; 55910-632; 0338-0056; 0338-9159; 65219-218; 65219-432; 67091-327; 70529-024; 71309-154; 0641-0497; 76472-1154; 76472-4096; 77333-835; 77333-844; 0990-6138; 51552-0077; 0990-7972; 0990-7985; 55154-9357; 0338-0048; 0338-0049; 59779-303; 63323-099; 0363-5557; 65219-224; 65219-228; 68428-061; 69842-473; 70529-023; 71872-7082; 0641-1512; 76472-4026; 80762-0011; 10106-3302; 24600-1382; 63822-0001; 51662-1522; 0363-0193; 62106-1058; 63323-139; 64253-202; 0404-9954; 68428-111; 68428-526; 0409-6660; 69842-472; 0990-7984; 69500-110; 70387-115; 17478-623; 42829-407; 42829-504; 49281-912; 0019-1188; 0220-3595; 0220-3600; 52584-109; 55154-0126; 58657-118; 0338-0043; 0338-0164; 0338-0196
UNII 451W47IQ8X
Synonyms Sodium Chloride | Sodium Chloride, (22)Na | Sodium Chloride, (24)NaCl
Chemical Information
Molecular Formula ClNa
CAS Registry Number 7647-14-5
SMILES [Na+].[Cl-]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Systemic inflammatory response syndrome08.01.05.005; 10.02.01.008; 24.06.03.0080.000241%-
Injection site discolouration08.02.03.038; 12.07.03.038; 23.03.03.0460.000821%-
Conjunctival hyperaemia06.04.01.0040.000362%-
Musculoskeletal discomfort15.03.04.001---
Inappropriate antidiuretic hormone secretion05.03.03.001; 14.05.07.0010.000531%-
Skin swelling23.03.03.0390.000241%-
Injection site swelling08.02.03.017; 12.07.03.0180.001183%-
Infusion site pain08.02.05.014; 12.07.05.0020.000531%-
Type IV hypersensitivity reaction10.01.03.0220.000241%-
Injection site discomfort08.02.03.018; 12.07.03.019---
Haemorrhagic transformation stroke17.08.01.036; 24.07.04.0180.000241%-
Haemorrhage24.07.01.0020.001569%-
Fluid intake reduced14.05.10.001---
Gaze palsy06.05.02.014; 17.02.05.0440.000241%-
Temperature intolerance08.01.09.0220.003983%-
Hypoaesthesia oral07.05.05.003; 17.02.06.0210.000362%-
Breast cancer female16.10.01.004; 21.05.01.011---
Bipolar disorder19.16.01.003---
Cognitive disorder17.03.03.003; 19.21.02.001--
Injection site nodule08.02.03.034; 12.07.03.034; 23.07.04.009---
Metabolic disorder14.11.01.0010.000241%-
Pulseless electrical activity02.03.04.0200.000241%-
Lung neoplasm malignant16.19.02.001; 22.08.01.001---
Cerebrovascular insufficiency17.08.02.003; 24.04.06.004---
Injection site scar08.02.03.050; 12.07.03.050; 23.03.11.016---
Metastases to central nervous system16.22.02.004; 17.02.10.013---
Infusion site rash08.02.05.017; 12.07.05.017; 23.03.13.0180.000241%-
Neurological symptom17.02.05.0100.000362%-
Adverse event08.06.01.010---
Appetite disorder14.03.01.004; 19.09.01.0020.000241%-
The 14th Page    First    Pre   14 15 16 17    Next   Last    Total 17 Pages